

1 Cohort Profile: A longitudinal Victorian COVID-19 cohort (COVID PROFILE)

2 Emily M. Eriksson,^{1,2#} Anne Hart,¹ Maureen Forde,¹ Siavash Foroughi,^{1,2} Nicholas
3 Kiernan-Walker,¹ Ramin Mazhari,^{1,2} Erin C. Lucas,¹ Mai Margetts,¹ Anthony
4 Farchione,¹ Dylan Sheerin,^{1,2} George Ashdown,^{1,2} Rachel Evans,¹ Catherine Chen,^{1,2}
5 Shazia Ruybal-Pesántez,^{1,2,3} Eamon Conway,^{1,2} Marilou H. Barrios,^{1,2} Jasper
6 Cornish,^{1,2} Maria Edmonds,¹ Lee M. Henneken,^{1,4} Lisa J. Ioannidis,^{1,2} Sam W. Z.
7 Olechnowicz,^{1,2} Ryan B. Munnings,¹ Joanna R. Groom,^{1,2} Diana S. Hansen,^{1,2} Rory
8 Bowden,^{1,2} Anna K. Coussens,^{1,2,5} Jason A. Tye-Din,^{1,2,4,6} Vanessa L. Bryant,^{1,2,7} and
9 Ivo Mueller^{1,2}

10 # Corresponding author

11

12 1. Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia

13 2. The University of Melbourne, Department of Medical Biology, Parkville, VIC 3052,
14 Australia

15 3. MRC Centre for Global Infectious Disease Analysis, Department of Infectious
16 Disease Epidemiology, Imperial College London, UK

17 4. Department of Gastroenterology, The Royal Melbourne Hospital, Parkville, VIC
18 3052, Australia

19 5. Wellcome Centre for Infectious Diseases Research in Africa, Department of
20 Pathology, Institute of Infectious Diseases and Molecular Medicine, University of
21 Cape Town, South Africa 3079.

22 6. Centre for Food & Allergy Research, Murdoch Children's Research Institute,
23 Parkville, VIC, Australia

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 7. Dept Clinical Immunology and Allergy, The Royal Melbourne Hospital, Parkville,

25 3050

26

27

28 Corresponding Author:

29 Emily M. Eriksson

30 The Walter and Eliza Hall Institute of Medical Research

31 1G Royal Parade, Parkville, VIC 3052 Australia

32 Tel: +61 3 93452870

33 email: eriksson@wehi.edu.au

34 **Abstract**

35 **Purpose:** The COVID PROFILE cohort is a longitudinal clinical study based in Victoria
36 Australia, which was established to understand immunity to SARS-CoV-2 in a *low*
37 *transmission population setting* and to identify immunological markers of long-term
38 immunity and immune-dysregulation after both infection and vaccination. Additionally,
39 this cohort was established as a biobank resource for researchers to address other
40 health-related immunological questions.

41 **Participants:** We enrolled 178 adult community members, including household
42 contacts, who had either recovered from a SARS-CoV-2 infection or were SARS-CoV-
43 2 naïve. Only participants ≥ 18 years of age and, in the case of female participants,
44 non-pregnant women at the time of enrollment were included in the study. Detailed
45 COVID-19 clinical data, vaccination status, medical history and demographics was
46 collected.

47 **Findings to date:** At enrollment, we found that 87.8% of COVID-19 recovered
48 individuals were seropositive with detectable levels of anti-SARS-CoV-2 IgG
49 antibodies. Seronegative COVID-19 recovered individuals included asymptomatic
50 individuals or participants that were enrolled more than 12 months after their COVID-
51 19 diagnosis. Except for one individual who was seropositive at baseline despite a
52 previous SARS-CoV-2 PCR negative diagnosis, all household contacts and other
53 community members enrolled as SARS-CoV-2 PCR negative, were seronegative for
54 all SARS-CoV-2-specific antibodies tested. The infection rate (re-infection or new
55 infection) during 24 months of the study was 42.7%, as determined by either rapid
56 antigen tests, PCRs or serology screens. Of the SARS-CoV-2 recovered participants,
57 32.6% reported ongoing symptoms at enrollment of which 47% had already
58 experienced ongoing symptoms for more than 12 weeks.

59 **Future Plans:** COVID PROFILE will be used to comprehensively understand temporal
60 immunity to SARS-CoV-2 and COVID-19 vaccines and to understand the impact of
61 host immunological composition on such immunity and symptom severity. Additionally,
62 studies focusing on understanding immunity following breakthrough infections and
63 immunological risk factors that contribute towards development of long COVID are
64 planned.

65

66 **Limitations/Strengths of the study**

- 67 • Extensive clinical information is available and longitudinal samples (blood,
68 saliva and oropharyngeal swabs) collected at regular intervals up to 2.5 years
69 after initial enrolment.
- 70 • This low SARS-CoV-2 transmission population cohort, enables exploration of
71 difference in both the acquisition and maintenance of naturally acquired and
72 vaccine-induced immunity not confounded by prior, frequent and/or undetected
73 exposures.
- 74 • Extensive biobank of numerous blood fractions and biospecimen enables
75 further exploration of mucosal immunity, nasal microbiome and humoral and
76 cellular immunity over time.
- 77 • The cohort may be limited in addressing research questions regarding
78 outcomes and risk factors and their associations where low incidence is
79 expected.

80

81

82 **Introduction and Cohort description**

83 The first case of SARS-CoV-2 recorded in Australia was on January 25th 2020, only
84 25 days after the first case had been reported to the World Health Organisation (1).
85 This was followed by intense national efforts to diminish and if possible, eliminate
86 SARS-CoV-2 transmission. While transmission was not immediately contained and
87 resulted in a peak of confirmed SARS-CoV-2 positive cases in late March followed by
88 a second peak in July, community transmission was largely undetectable by October
89 2020 (2) (**Fig. 1**). This pandemic response, which included international and domestic
90 border closures, lockdowns and Australia's geographical inaccessibility resulted in
91 overall comparatively low case numbers and thus a distinctively SARS-CoV-2 naïve
92 population prior to COVID-19 vaccine rollout in February 2021. Furthermore, unlike
93 the majority of populations across the world, the Australian population remained
94 largely unexposed until end of 2021 (**Fig.1**).

95 The COVID PROFILE study was launched in Melbourne, Victoria in October 2020 to
96 follow COVID-19 recovered individuals over a year of enrollment, being in a relatively
97 unique position to understand longevity of immunity to SARS-CoV-2 infection where
98 risk of continuous re-exposure was low. This study was approved by the Walter and
99 Eliza Hall Institute (WEHI) and Melbourne Health Human Research Committees
100 (Projects 20/08 and RMH69108 respectively). All enrolled participants provided written
101 informed consent to participate in this study, in accordance with the Declaration of
102 Helsinki. Most participants were enrolled between October 2020 and June 2021.
103 SARS-CoV-2 recovered participants were predominantly infected locally during the
104 second July-September 2020 infection wave (71.4%) and the remaining participants
105 contracted SARS-CoV-2 from the first infection wave (March-May 2020) or were
106 infected overseas (**Fig. 1**). The only circulating SARS-CoV-2 variant at the time of

107 these infections was the ancestral (Wuhan) strain resulting in a homogenously
108 exposed population (**Fig. 1**). The study visit schedule consisted of a baseline visit (at
109 enrollment), 4-6 weeks post-diagnosis where possible, followed by visits at 3, 6, 9 and
110 12 months post-enrollment (**Fig. 2**). Following the roll out of COVID-19 vaccines in
111 Australia in Feb 2021, that consisted predominantly of ChAdOx1-S (AstraZeneca) or
112 BNT162b2 (Pfizer), participants already enrolled in the study were invited to continue
113 follow-up for up to 12 months after their second dose of vaccine. Additional SARS-
114 CoV-2 naïve individuals were invited to take part in the study before their first COVID-
115 19 vaccination and for these newly recruited participants, a baseline pre-vaccination
116 sample was also collected. Post-vaccination follow-up visits consisted of sample
117 collection 2-4 weeks after each dose of vaccine and then 3, 6, 9 and 12 months after
118 the second dose, unless another exposure event such as an additional vaccination or
119 breakthrough infection occurred. Follow-up was then extended for up to 12 months
120 after each exposure, following a visit schedule comparable to that previously defined
121 (**Fig. 2**). Biospecimens consisting of blood, saliva, and oropharyngeal swabs were
122 collected at all visits where blood specimens were stored as serum, plasma,
123 cryopreserved peripheral blood mononuclear cells (PBMCs), frozen and fixed whole
124 blood and in some cases neutrophils. Oropharyngeal swabs were collected and stored
125 in sample preservation medium in their original tubes at -80°C until required. Detailed
126 COVID-19 clinical data, vaccination status, medical history and demographics (both
127 during acute infection and long-term follow up) was collected and study data were
128 managed using REDCap electronic data capture tools hosted by the Clinical
129 Translation Centre, WEHI, Parkville, Victoria, Australia (3, 4).

130

131 **Participant demographics**

132 To date, 178 participants have been recruited to the COVID PROFILE study following
133 advertising campaigns via social media, primary care networks and tertiary teaching
134 hospital. Seven participants failed to provide a baseline sample as specified in the
135 study schedule and were excluded from the study and all analyses (**Fig. 3**). Ninety-
136 eight participants were SARS-CoV-2 recovered and 73 were SARS-CoV-2 naïve at
137 enrolment. The participants comprised 122 separate households: 88 households with
138 1 participant, 26 households with 2 participants, 1 household with 3 participants and 7
139 households with 4 participants. Gender distribution was 59.1% female (n = 101) in the
140 overall cohort and 63.3% female (n = 62) in the COVID-19-recovered group. Overall
141 age distribution in the cohort ranged from 18 to 90 years of age with a median age of
142 46 years. Median age for the SARS-CoV-2 naïve group was 44 years (range 18 – 90
143 years) and 49 years for the SARS-CoV-2 recovered group (range 19 – 75 years, **Fig.**
144 **4**), which resemble the overall distribution of nationwide adult cases in 2020 (5).

145

146 Self-reported acute disease symptoms and duration were collected at enrolment and
147 after subsequent breakthrough infections. Acute disease status was classified as
148 “severe disease” if hospitalisation was required due to the infection, regardless of
149 whether intubation or oxygen supplementation was necessary. All other participants
150 with any symptoms were categorised as mild/moderate (78.6%; n=77) or
151 asymptomatic (3.1%; n=3) in cases of self-reported absence of symptoms (**Fig. 3**). A
152 substantial proportion of participants were categorised as severe (18.4%; n=18), which
153 was higher than the reported national rate of 12.5% hospitalisation in 2020 due to
154 COVID-19 (6).

155

156 *COVID-19 vaccine status*

157 During follow up most participants received at least 2 doses of COVID-19 vaccines
158 (81.9%). The breakdown of vaccine type received as primary vaccination is
159 summarised in **Fig. 5**. Participants predominately received Pfizer (60%, median age =
160 40.5 years) and AstraZeneca (37.1%, median age = 56.5 years) with only a few
161 receiving Moderna-Spikevax (0.7%) or Novavax (2.1%). A subset of the vaccinated
162 participants have also received a third (43.4%) and fourth (35.7%) dose of vaccine of
163 either Pfizer or Moderna-Spikevax.

164 **Findings to date**

165 To establish the serostatus of participants, SARS-CoV-2-specific IgG antibodies were
166 measured at baseline for all participants using a Luminex multiplex assay (7). This
167 assay measures antibodies that recognize and bind to full-length Spike, receptor-
168 binding domain (RBD), S1, S2 and nucleoprotein, all based on the Wuhan variant
169 sequence. In addition, antibodies specific for seasonal coronavirus proteins (NL63,
170 HKU1, OC43 and 229E), tetanus toxoid and Influenza A (H1N1) were also measured
171 as controls. Serostatus based on measured anti-SARS-CoV-2 antibody levels was
172 determined using a random forest classification algorithm. Most participants who had
173 a PCR+ diagnosis at enrolment were seropositive (87.8%) at baseline. Amongst the
174 COVID-19 recovered individuals who had a PCR+ diagnosis but were seronegative at
175 enrolment (n=12), three presented as asymptomatic individuals, four participants were
176 enrolled more than 12 months after their COVID-19 diagnosis and the remaining
177 seronegative individuals were within 6 months of diagnosis. The majority of individuals
178 that were enrolled as PCR negative participants (99%) were also seronegative, with
179 only one participant who had previously had a negative PCR diagnosis shortly before
180 sample collection, was found to be seropositive.

181

182 As part of the extensive longitudinal clinical data collected for this study, a substantial
183 proportion of SARS-CoV-2 recovered participants (32.6% of 98 SARS-CoV-2
184 recovered individuals) reported ongoing symptoms at the time of enrolment of which
185 47% had already experienced symptoms persisting for 12 weeks or longer, meeting
186 the current criteria for long COVID (8).

187

188 The longitudinal design of our study captured multiple breakthrough infections (42.4%)
189 in our participants over the course of 24 months. Most such detections came from
190 rapid antigen tests (RATs), precluding the identification of the infecting variant.
191 However, 98.3% of breakthrough infections coincided with the period during which
192 Omicron was the dominant variant in Australia (9). Most breakthrough infections were
193 detected after three COVID-19 vaccine doses (65.5%) but they also occurred after two
194 (15.5%) and four (19%) doses of COVID-19 vaccines

195

196 **Future plans**

197 Sample collection is expected to be completed in June 2023 after which samples will
198 support in-depth analysis to understand temporal humoral and cellular responses to
199 infection, COVID-19 vaccines and breakthrough infections with different variants. We
200 have so far collected and bio banked > 8300 biospecimens, which include serum,
201 whole blood, oropharyngeal swabs, plasma, PBMCs and saliva samples across 1200
202 visits over 24 months. Furthermore, given the detailed medical history recorded and
203 the relatively high frequency of participants reporting long COVID in our cohort,
204 additional analyses are planned to explore specific biomarkers and underlying
205 processes involved with this condition.

206

207 **Patient and public involvement**

208 The participants were not involved in the study's design or conclusions. Participants
209 were informed of serological results via email.

210

211 **Limitations/Strengths**

212 The COVID PROFILE is a cohort study where extensive clinical information is
213 available and longitudinal blood samples, saliva and oropharyngeal swabs collected
214 at regular intervals up to 2.5 years after initial enrolment will have been accumulated
215 at the completion of the study. This included samples collected in naive individuals
216 with subsequent infection. Low SARS-CoV-2 transmission in Australia before January
217 2022, provides an opportunity to explore difference in both the acquisition and
218 maintenance of naturally acquired and vaccine-induced immunity (or a combination
219 thereof), as well as differences in vaccine response in people with a single or no
220 previous exposure to SARS-CoV-2. This also provides a unique opportunity to support
221 research questions not confounded by prior, frequent and/or undetected exposures
222 using a highly curated and clinically annotated biobank of samples. We anticipate the
223 COVID PROFILE cohort will also provide great value as a comparative cohort set to
224 other studies in high transmission countries. Our extensive biobank includes
225 numerous blood fractions and biospecimen types collected longitudinally, which
226 further enables the exploration of mucosal immunity, nasal microbiome and humoral
227 and cellular immunity over time. However, due to its relatively small size, the cohort
228 may be limited in addressing research questions regarding outcomes and risk factors
229 and their associations where low incidence is expected.

230

231

232

233 **Collaboration** The authors are welcoming and encouraging research collaborations
234 using the COVID PROFILE samples for population and/or immunological questions.
235 Samples and/or data are available on reasonable request and researchers are
236 welcome to contact the research group for further information.

237

238 **Data availability statement**

239 Samples and/or data are available upon reasonable request. Research proposals for
240 future collaboration are welcome. Applicants for collaboration and more information
241 are encouraged to contact the corresponding author Dr. Emily M Eriksson (Email
242 address: eriksson@wehi.edu.au).

243


244 References

- 245 1. Shaban RZ, Li C, O'Sullivan MVN, Gerrard J, Stuart RL, Teh J, et al. COVID-19 in
246 Australia: our national response to the first cases of SARS-CoV-2 infection during the early
247 biocontainment phase. *Intern Med J.* 2021;51(1):42-51.
- 248 2. [https://www.health.gov.au/resources/publications/coronavirus-covid-19-at-a-](https://www.health.gov.au/resources/publications/coronavirus-covid-19-at-a-glance-20-december-2020)
249 [glance-20-december-2020](https://www.health.gov.au/resources/publications/coronavirus-covid-19-at-a-glance-20-december-2020). [Available from:
250 [https://www.health.gov.au/resources/publications/coronavirus-covid-19-at-a-glance-20-](https://www.health.gov.au/resources/publications/coronavirus-covid-19-at-a-glance-20-december-2020)
251 [december-2020](https://www.health.gov.au/resources/publications/coronavirus-covid-19-at-a-glance-20-december-2020).
- 252 3. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap
253 consortium: Building an international community of software platform partners. *J Biomed*
254 *Inform.* 2019;95:103208.
- 255 4. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic
256 data capture (REDCap)--a metadata-driven methodology and workflow process for providing
257 translational research informatics support. *J Biomed Inform.* 2009;42(2):377-81.
- 258 5. [https://www.health.gov.au/resources/publications/coronavirus-covid-19-at-a-](https://www.health.gov.au/resources/publications/coronavirus-covid-19-at-a-glance-30-september-2020)
259 [glance-30-september-2020](https://www.health.gov.au/resources/publications/coronavirus-covid-19-at-a-glance-30-september-2020). [Available from:
260 [https://www.health.gov.au/resources/publications/coronavirus-covid-19-at-a-glance-30-](https://www.health.gov.au/resources/publications/coronavirus-covid-19-at-a-glance-30-september-2020)
261 [september-2020](https://www.health.gov.au/resources/publications/coronavirus-covid-19-at-a-glance-30-september-2020).
- 262 6. [https://www.aihw.gov.au/reports/burden-of-disease/the-first-year-of-covid-19-in-](https://www.aihw.gov.au/reports/burden-of-disease/the-first-year-of-covid-19-in-australia/summary)
263 [australia/summary](https://www.aihw.gov.au/reports/burden-of-disease/the-first-year-of-covid-19-in-australia/summary). [Available from: [https://www.aihw.gov.au/reports/burden-of-](https://www.aihw.gov.au/reports/burden-of-disease/the-first-year-of-covid-19-in-australia/summary)
264 [disease/the-first-year-of-covid-19-in-australia/summary](https://www.aihw.gov.au/reports/burden-of-disease/the-first-year-of-covid-19-in-australia/summary).
- 265 7. Mazhari R, Ruybal-Pesantez S, Angrisano F, Kiernan-Walker N, Hyslop S, Longley RJ,
266 et al. SARS-CoV-2 Multi-Antigen Serology Assay. *Methods Protoc.* 2021;4(4).
- 267 8. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, Condition WHOCCDWGoP-C-. A
268 clinical case definition of post-COVID-19 condition by a Delphi consensus. *Lancet Infect Dis.*
269 2022;22(4):e102-e7.
- 270 9. [https://ourworldindata.org/grapher/covid-variants-](https://ourworldindata.org/grapher/covid-variants-bar?country=USA~GBR~ESP~ZAF~ITA~DEU~FRA~CAN~BEL~AUS)
271 [bar?country=USA~GBR~ESP~ZAF~ITA~DEU~FRA~CAN~BEL~AUS](https://ourworldindata.org/grapher/covid-variants-bar?country=USA~GBR~ESP~ZAF~ITA~DEU~FRA~CAN~BEL~AUS). [Available from:
272 [https://ourworldindata.org/grapher/covid-variants-](https://ourworldindata.org/grapher/covid-variants-bar?country=USA~GBR~ESP~ZAF~ITA~DEU~FRA~CAN~BEL~AUS)
273 [bar?country=USA~GBR~ESP~ZAF~ITA~DEU~FRA~CAN~BEL~AUS](https://ourworldindata.org/grapher/covid-variants-bar?country=USA~GBR~ESP~ZAF~ITA~DEU~FRA~CAN~BEL~AUS).
- 274 10. [https://www.health.gov.au/resources/publications/coronavirus-covid-19-at-a-](https://www.health.gov.au/resources/publications/coronavirus-covid-19-at-a-glance-31-december-2021)
275 [glance-31-december-2021](https://www.health.gov.au/resources/publications/coronavirus-covid-19-at-a-glance-31-december-2021).

277

278 Figures and Figure Legends

Figure 1



279

280 **Figure 1. Schematic of COVID-19 pandemic in Australia 2020-2022.** Schematic


281 timeline showing daily reported cases in Australia (2, 10) between Feb 2020 to Jan

282 2022 with indicated dominant infective variant identified in reported cases over time

283 (9). Created with BioRender.com

284

Figure 2



285


286 **Figure 2. Study design and participant visit schedule**

287 SARS-CoV-2 recovered participants were enrolled and followed for up to 12 months
288 after enrollment with sample collection at baseline (at enrollment) and 3, 6, 9 and 12
289 months after enrollment (green line). SARS-CoV-2 naïve participants provided a
290 baseline sample (purple line). Biospecimen samples were collected from COVID-19
291 vaccinated participants 2-4 weeks after each vaccine dose and then at 3, 6, 9 and 12
292 months after the final dose (purple and blue line). Samples were also collected 2-4
293 weeks after breakthrough infections and again at 3, 6, 9 and 12 months after the
294 diagnosis (pink line). Saliva, oropharyngeal swabs, serum and whole blood were
295 collected and stored after each visit.

296 Created with BioRender.com

297


Figure 3



298

299 **Figure 3. Summary of participant categories.** Cohort participants stratified based
300 on infection status at enrollment. Further stratification of SARS-CoV-2 recovered
301 individuals based on disease status.

302




303

304 **Figure 4. Cohort age and gender profile.** Participant age range is 18-90 years; blue:

305 male; orange: female.

306

Figure 5



307
308 **Figure 5. Summary of vaccine status of participants.** Cohort participants stratified
309 based on disease status at time of enrollment and vaccine status after two doses of
310 COVID-19 vaccine. Vaccine recipients were further stratified based on the type of
311 COVID-19 vaccine received; Pfizer (BNT162b2), AstraZeneca (ChAdOx1-S),
312 Moderna- Spikevax or Novavax.
313

314 **Funding:** This work was made possible through Victorian State Government
315 Operational Infrastructure Support and Australian Government NHMRC IRIISS. This
316 work was supported by WHO Unity funds (2020/1085469-0) and WEHI Philanthropic
317 funds. The funders had no role in study design, data collection and analysis.

318

319 **Author Contributions:** EME and IM conceived and initiated the study. EME, IM, VLB
320 and JATD were the principal investigators of the study. EME established study
321 protocols and oversaw clinical, technical and data analysis staff. EME, RB and AKC
322 established sample processing procedures. EME and SF wrote the manuscript. AH
323 and MF were study coordinators managing recruitment, enrolment, collected samples
324 and obtained clinical and demographic data. SF managed the Redcap database.
325 NKW, RM, ECL, MM, AF, DS, GA, RE, CC, MHB, JC, LJI, SWZO, and RBM provided
326 technical assistance. ME and LMH assisted with sample collection. SF, SRP and EC
327 managed data analysis. IM, VLB, JATD, JRG, DSH, RB and AKC critically reviewed
328 the manuscript. All authors read and approved submission of the manuscript.

329

330 **Acknowledgments**

331 We gratefully acknowledge all the participants of this project and St Vincent's hospital
332 nurses for assistance with home visits and sample collection. We also thank all
333 administrative and communications staff and personnel for their support.